Immunocore Holdings plc
NASDAQ•IMCR
CEO: Dr. Bahija Jallal Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-02-05
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Contact Information
Market Cap
$1.57B
P/E (TTM)
-58.4
17.5
Dividend Yield
--
52W High
$40.72
52W Low
$23.15
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q4 2025 Data
Revenue
$77.43M+0.00%
4-Quarter Trend
EPS
-$0.44+0.00%
4-Quarter Trend
FCF
-$35.54M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
KIMMTRAK Revenue Surges Net therapy revenue reached $400.02M in 2025, marking a 29% increase driven by strong global adoption.
Strong European Sales Growth European revenue grew 79% to $131.42M in 2025, reflecting successful expansion efforts outside the US market.
Pipeline Advancement Progresses Submitted CTA for autoimmune candidate IMC-S118AI in December 2025; advancing multiple Phase 3 oncology trials.
Healthy Cash Position Maintained Ended 2025 with $467.71M in cash and equivalents, supporting ongoing operations despite net losses incurred.
Risk Factors
Continued Operating Losses Incurred net losses of $35.51M in 2025; accumulated deficit reached $(831.3)M since inception.
Commercialization Acceptance Risk Success highly dependent on market acceptance of KIMMTRAK among physicians, payors, and medical community.
Regulatory Approval Uncertainty Future product approvals face risks from evolving regulatory pathways, potential clinical trial delays, and data interpretation issues.
Need for Future Capital Expect significant operating losses to continue, requiring substantial additional financing for long-term development plans.
Outlook
Grow KIMMTRAK Lifecycle Program Prepare for new melanoma indications; expect topline data from TEBE-AM Phase 3 trial in second half 2026.
Expand Oncology Pipeline Readouts Anticipate multiple Phase 1 readouts for PRAME bispecific candidates across various tumor types during 2026.
Advance Non-Oncology Candidates Plan Phase 1 trial initiation for IMC-S118AI (Type 1 Diabetes) in first half 2026; file CTA for IMC-U120AI later.
Peer Comparison
Revenue (TTM)
$1.12B
$868.45M
$372.97M
Gross Margin (Latest Quarter)
100.0%
100.0%
99.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| EWTX | $3.21B | -18.4 | -32.0% | 0.7% |
| VERA | $2.94B | -8.8 | -59.7% | 10.5% |
| VRDN | $2.41B | -7.0 | -58.4% | 5.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.2%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data